In the complete response letter regarding the New Drug Application (NDA) for Bydureon (exenatide extended-release for in…
Injectable Medication
FDA Requests Further Testing On Amylin’s New Type 2 Diabetes Drug
In the complete response letter regarding the New Drug Application (NDA) for Bydureon (exenatide extended-release for in…
Type 2 Diabetes Patients Prefer Injectable Victoza to Oral Januvia
New Patient Reported Outcomes (PRO) data presented by today at the European Association for the Study of Diabetes (EASD)…
Sanofi-aventis’ Once-Daily Type 2 Diabetes Drug Lixisenatide Shows Significant Improvement in Glucose Control
Sanofi-aventis announced the first Phase III results of the GetGoal clinical trial program assessing the efficacy and sa…
Novo Nordisk GlucaGen Hypokit Being Recalled in Canada
Health Canada is informing Canadians that Novo Nordisk Canada Inc. has agreed to voluntarily recall two lots (YW60335 an…
All About Victoza: An Interview with Novo Nordisk’s Dr. Alan Moses
Incretin-based treatments target the beta cell and enhance the release of insulin based on the amount of glucose in the …
Byetta Improves Beta-Cell Function in Type 2 Diabetics
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced results from a study comparing the effect of long-term …
Byetta Helps Type 2 Diabetics Achieve Blood Glucose Control
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced results from the first double-blind, placebo-controlled…
Symlin Does Not Increase Risk of Cardiovascular Event, New Study Shows
Amylin Pharmaceuticals, Inc. announced results from an analysis of an integrated database of clinical studies that showe…
Victoza Superior to Januvia, New Study Shows
Late-breaking Novo Nordisk extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Asso…
